Quantitative Radiomic Biomarkers for Whole-Body Health Assessment

Abstract

Quantitative radiomic biomarkers have rapidly emerged as transformative tools in the field of medical imaging, offering a noninvasive, high-throughput approach to characterizing whole-body health at the tissue and organ levels. By extracting and analyzing complex imaging features from modalities such as MRI, CT, and PET, radiomics enables clinicians to move beyond visual interpretation, supporting more precise and personalized health assessments. This review synthesizes recent evidence on the clinical utility, mechanism-based rationale, and guideline integration of quantitative radiomic biomarkers in comprehensive health assessment, highlighting their applications, benefits, potential pitfalls, and future directions for research and practice.

Introduction

The advent of radiomics has revolutionized the quantitative analysis of medical images, shifting the paradigm from subjective assessment to objective, data-driven evaluation. Quantitative radiomic biomarkers refer to the numerical descriptors extracted from medical images that capture tissue heterogeneity, morphology, texture, and functional characteristics. These biomarkers have demonstrated significant promise in oncology, cardiology, neurology, and metabolic disease, providing insights into disease processes that often elude conventional imaging. Their application for whole-body health assessment offers the potential to identify early pathological changes, stratify risk, and guide therapeutic decisions, thereby enhancing patient outcomes and optimizing resource allocation in healthcare systems.

Epidemiology / Disease Burden

Chronic diseases such as cancer, cardiovascular disease, and metabolic disorders remain leading causes of morbidity and mortality worldwide. Early detection and accurate risk stratification are fundamental to effective disease management, yet current approaches often rely on invasive procedures or limited imaging criteria. The ability of radiomic biomarkers to quantify subclinical changes across multiple organ systems, using already-acquired whole-body imaging, addresses an unmet need in population health surveillance. Epidemiological studies increasingly leverage radiomics to identify at-risk individuals, monitor disease trajectory, and evaluate response to interventions at a population scale, with ongoing research focusing on the generalizability and reproducibility of these methods across diverse cohorts.

Pathophysiology

Radiomic biomarkers capture pathophysiological alterations at the micro-architectural level, reflecting processes such as fibrosis, inflammation, neovascularization, and cellular heterogeneity. For example, in oncology, radiomic texture analysis can differentiate between benign and malignant lesions by quantifying heterogeneity associated with tumor angiogenesis and necrosis. In cardiovascular disease, quantitative features derived from cardiac MRI or CT can reveal subtle changes in myocardial tissue composition, fatty infiltration, or microvascular disease, preceding overt clinical manifestations. These mechanistic insights enable a deeper understanding of disease biology and facilitate the identification of novel therapeutic targets.

Risk Factors

Traditional risk factors such as age, genetics, lifestyle, and comorbid conditions remain central to disease prediction models. However, radiomic biomarkers provide additional, imaging-derived risk information that complements established risk scores. For instance, radiomics-based quantification of visceral adiposity, hepatic steatosis, or coronary artery plaque characteristics can enhance cardiovascular risk stratification beyond conventional clinical and biochemical markers. Integrating radiomic features with electronic health records, genomics, and other omics data expands the scope for precision risk assessment and early intervention strategies.

Clinical Features

Quantitative radiomic biomarkers facilitate the characterization of clinical phenotypes that may not be readily apparent on standard imaging. In oncology, radiomics can distinguish aggressive tumor subtypes, predict lymph node involvement, and anticipate metastatic potential. In musculoskeletal and metabolic disorders, radiomic texture and shape features can indicate early osteoarthritis, sarcopenia, or organ fibrosis before clinical symptoms develop. The ability to noninvasively phenotype disease across the entire body opens avenues for holistic health monitoring and tailored clinical management.

Diagnosis

Radiomic biomarkers augment diagnostic accuracy by providing objective, reproducible metrics that support radiological interpretation. Machine learning algorithms trained on radiomic data have demonstrated superior performance in differentiating benign from malignant lesions, classifying tumor grade, and predicting response to therapy compared to human experts alone. In whole-body health assessment, radiomics enables the simultaneous evaluation of multiple organ systems, supporting early diagnosis of complex, multisystem diseases. Standardization efforts are ongoing to harmonize feature extraction protocols and ensure consistency across imaging platforms and institutions.

Treatment & Management

The integration of radiomic biomarkers into clinical workflows informs treatment selection, monitoring, and prognostication. In oncology, radiomics-guided decision-making can identify candidates for aggressive therapy or surveillance, monitor tumor response during treatment, and detect early recurrence. In chronic diseases, serial radiomic assessment allows for quantification of disease progression or regression in response to lifestyle interventions or pharmacotherapy. This data-driven approach supports personalized medicine, minimizing overtreatment and optimizing therapeutic efficacy.

Recent Advances / Emerging Therapies

Recent advances have focused on the development of multiparametric radiomic signatures that combine features from different imaging modalities, enhancing diagnostic and prognostic power. Artificial intelligence (AI) and deep learning models now enable more sophisticated feature extraction and pattern recognition, expanding the applications of radiomics to rare and complex diseases. Emerging research explores radiogenomics, which integrates radiomic and genomic data to elucidate molecular underpinnings of disease. The use of federated learning and large, multi-institutional datasets addresses issues of data privacy and generalizability, accelerating the translation of radiomics into routine practice.

Guideline Recommendations

Professional societies increasingly recognize the potential of quantitative radiomic biomarkers in clinical guidelines. The Quantitative Imaging Biomarkers Alliance (QIBA) and the Radiological Society of North America (RSNA) have published consensus statements emphasizing the need for standardization, validation, and reporting transparency. Current recommendations advocate for the incorporation of radiomic analysis in clinical trials, particularly in oncology, and encourage multidisciplinary collaboration between radiologists, data scientists, and clinicians to ensure clinical relevance and utility. Ongoing efforts aim to establish clear pathways for regulatory approval and reimbursement, facilitating broader adoption in clinical practice.

Conclusion

Quantitative radiomic biomarkers represent a paradigm shift in whole-body health assessment, offering unprecedented opportunities for noninvasive, comprehensive, and personalized patient care. By integrating advanced image analytics into routine clinical practice, radiomics enables earlier detection, refined risk stratification, and tailored management across a spectrum of diseases. Continued research, standardization, and cross-disciplinary collaboration will be critical to fully realize the clinical potential of radiomic biomarkers and to ensure their safe, effective, and equitable implementation in healthcare systems worldwide.